心元胶囊对慢性心力衰竭心血瘀阻证患者心脏超声参数、脂质代谢及血液流变学的影响

摘要 目的：探讨心元胶囊对慢性心力衰竭（CHF）心血瘀阻证患者心脏超声参数、脂质代谢及血液流变学的影响。方法：根据随机数字表法，将我院2020年3月~2022年3月期间收治的的CHF心血瘀阻证患者120例分为对照组（常规西药治疗，n=60）和观察组（心元胶囊联合常规西药治疗，n=60）。对比两组中医疗效、心功能指标、血脂指标、肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、N-末端脑钠肽前体（NT-proBNP）、血液流变学指标，并观察两组不良反应情况。结果：观察组的中医总有效率明显高于对照组（P<0.05）。两组治疗后左室射血分数升高，左室舒张末期容量、左室收缩末期容量缩小，且观察组的改善效果优于对照组（P<0.05）。两组治疗后三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）下降，高密度脂蛋白胆固醇（HDL-C）升高，且观察组的改善效果优于对照组（P<0.05）。两组治疗后CK、CK-MB、NT-proBNP下降，且观察组的改善效果优于对照组（P<0.05）。两组治疗后全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原下降，且观察组的改善效果优于对照组（P<0.05）。两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论：心元胶囊治疗CHF心血瘀阻证可提高临床疗效，改善心功能，调节脂质代谢、血液流变学水平，安全有效。

Effect of Xinyuan Capsule on Cardiac Ultrasound Parameters, Lipid Metabolism and Hemorrheology in Patients on Chronic Heart Failureand with Heart Blood Stasis Syndrome

ABSTRACT Objective: To investigate effect of Xinyuan capsule on cardiac ultrasound parameters, lipid metabolism and hemorrheology in patients on chronic heart failureand (CFH) with heart blood stasis syndrome. Methods: According to the method of random number table, 120 patients with CHF heart blood stasis syndrome who were admitted in our hospital from March 2020 to March 2022 were divided into the control group (conventional western medicine treatment, n=60) and the observation group (Xinyuan capsule combined with conventional western medicine treatment, n=60). The curative effect of traditional Chinese medicine, cardiac function indexes, blood lipid indexes, creatine kinase(CK), creatine kinase isoenzyme(CK-MB), N-terminal precursor of brain natriuretic peptide (NT-proBNP), blood rheology index in the two groups were compared, and the adverse reactions in two groups were observed. Results: The total effective rate of traditional Chinese medicine in the observation group was significantly higher than that in the control group (P<0.05). After treatment, left ventricular ejection fraction increased, left ventricular end diastolic volume and left ventricular end systolic volume decreased, and the improvement effect in the observation group was better than that in the control group(P<0.05). After treatment, triacylglycerol(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C) decreased and high-density lipoprotein cholesterol(HDL-C) increased in two groups, and the improvement effect in observation group was better than that in control group (P<0.05). CK, CK-MB, NT-proBNP decreased after treatment in the two groups, and the improvement effect in the observation group was better than that in the control group (P<0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and fibrinogen in the two groups decreased, and the improvement effect in the observation group was better than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups(P>0.05). Conclusion: Treatment of heart blood stasis syndrome in CHF by Xin Yuan capsule can improves clinical outcomes, improve cardiac function, regulate lipid metabolism and hemorheology of CHF, which is safe and effective.